You searched for
Category:
Innovation
Chiesi Marks Significant Step in its Net Zero Journey with MHRA Approval of its First Pressurized Metered-Dose Inhalers Containing a Next-Generation, Low GWP Propellant
20/07/2026
Chiesi and Oak Hill Bio Holdings complete patient enrollment in the Phase 2b FOOTPRINTS study
03/07/2026
U.S. FDA approves TRIMBOW® - Chiesi’s Single Inhaler Triple Therapy - for the maintenance treatment of asthma in adults
18/05/2026
MHRA Submission Marks New Step in Chiesi’s Carbon Minimal Inhaler Journey
18/12/2025
Chiesi Announces Discontinuation of the Tanimilast Program
03/11/2025
Chiesi Announces Results of the Tanimilast Phase III PILASTER Clinical Study in Chronic Obstructive Pulmonary Disease (COPD)
23/09/2025
Chiesi Group signs an Option Agreement with Inhibrx for Development and Commercialization of INBRX-101 (AAT-Fc)
30/05/2019